In the latest session, PDS Biotechnology Corporation (NASDAQ: PDSB) closed at $5.46 down -6.19% from its previous closing price of $5.82. In other words, the price has decreased by -$0.36 from its previous closing price. On the day, 1236186 shares were traded.
Ratios:
For a deeper understanding of PDS Biotechnology Corporation’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.21 and its Current Ratio is at 6.21. In the meantime, Its Debt-to-Equity ratio is 0.96 whereas as Long-Term Debt/Eq ratio is at 0.96.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, B. Riley Securities on November 01, 2022, initiated with a Buy rating and assigned the stock a target price of $10.
On June 28, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $25.
H.C. Wainwright Upgraded its Neutral to Buy on November 10, 2020, while the target price for the stock was maintained at $6.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PDSB now has a Market Capitalization of 169.85M and an Enterprise Value of 139.20M.
Stock Price History:
Over the past 52 weeks, PDSB has reached a high of $10.27, while it has fallen to a 52-week low of $3.80. The 50-Day Moving Average of the stock is 5.29, while the 200-Day Moving Average is calculated to be 5.43.
Shares Statistics:
For the past three months, PDSB has traded an average of 691.48K shares per day and 1.26M over the past ten days. A total of 30.17M shares are outstanding, with a floating share count of 29.59M. Insiders hold about 4.89% of the company’s shares, while institutions hold 26.46% stake in the company. Shares short for PDSB as of Feb 15, 2024 were 5.01M with a Short Ratio of 7.25, compared to 5.18M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 16.11% and a Short% of Float of 17.01%.
Earnings Estimates
There are 7 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.44 for the current quarter, with a high estimate of -$0.37 and a low estimate of -$0.6, while EPS last year was -$0.67. The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.41 and low estimates of -$0.46.
Analysts are recommending an EPS of between -$1.39 and -$1.53 for the fiscal current year, implying an average EPS of -$1.46. EPS for the following year is -$1.7, with 7 analysts recommending between -$1.21 and -$1.96.
